Key Segments:
By Product Type
-
Instruments
-
Kits and Consumables
-
Services
By Procedure Type
-
Tissue Biopsies
-
Liquid Biopsy
-
Others
By Cancer Type
-
Breast Cancer
-
Lung Cancer
-
Colorectal Cancer
-
Blood Cancer
-
Prostate Cancer
-
Pancreatic Cancer
-
Others
By End User
-
Hospitals
-
Ambulatory Surgical Centers
-
Diagnostic Laboratories
-
Cancer Research Institutes
By Application
-
Cancer Diagnosis and Staging
-
Treatment Monitoring
-
Cancer Screening
Regional Coverage:
North America
-
US
-
Canada
Europe
-
Germany
-
France
-
UK
-
Italy
-
Spain
-
Poland
-
Russia
-
Rest of Europe
Asia Pacific
-
China
-
India
-
Japan
-
South Korea
-
Australia
-
ASEAN Countries
-
Rest of Asia Pacific
Middle East & Africa
-
UAE
-
Saudi Arabia
-
Qatar
-
South Africa
-
Rest of Middle East & Africa
Latin America
-
Brazil
-
Argentina
-
Mexico
-
Colombia
-
Rest of Latin America
Available Customization
With the given market data, SNS Insider offers customization as per the company’s specific needs. The following customization options are available for the report:
-
Detailed Volume Analysis
-
Criss-Cross segment analysis (e.g. Product X Application)
-
Competitive Product Benchmarking
-
Geographic Analysis
-
Additional countries in any of the regions
-
Customized Data Representation
-
Detailed analysis and profiling of additional market players
Frequently Asked Questions
Key players include Becton, Dickinson and Company, Hologic, Inc., Danaher Corporation, Thermo Fisher Scientific Inc., and Roche Holding AG, among other diagnostics companies.
Continued advancement of comprehensive genomic and epigenomic profiling technology and continued inclusion of blood-based tests within national cancer screening guidelines represent the primary opportunities.
Growth is primarily driven by rising global cancer incidence, combined with growing demand for early diagnosis.
By Product Type, Kits and Consumables dominated the market with a 46.85% share in 2025, reflecting the recurring nature of biopsy procedure volume.
North America dominated the market with a 39.85% share in 2025, supported by growing demand for personalised medicine and broad cancer awareness.